PIMAVANSERIN (pimavanserin tartrate) by Acadia Pharmaceuticals is unclear. Approved for hallucinations, delusions associated with parkinson's disease psychosis. First approved in 2024.
Drug data last refreshed 1w ago
unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Pimavanserin and Aggression and Social Cognition.
Pimavanserin for Sleep in Parkinson Disease
Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept
Worked on PIMAVANSERIN at Acadia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.